Tumor Mutational Burden Reference Materials
SeraCare has released the first genomic DNA and formalin-fixed, paraffin-embedded reference materials for the measurement of tumor mutational burden via next-generation sequencing assays.
Read MorePosted by | Dec 19, 2019 | Standards |
SeraCare has released the first genomic DNA and formalin-fixed, paraffin-embedded reference materials for the measurement of tumor mutational burden via next-generation sequencing assays.
Read MorePosted by | Dec 19, 2019 | Clinical Chemistry, Research |
The Index at-home test is intended to enable individuals to test their cumulative rate of aging and determine their biological age—the average age at which their body is expected to perform.
Read MorePosted by | Dec 11, 2019 | Unknown Origin & Other Cancer Types |
FDA approval of Myriad’s new companion diagnostic advances precision medicine for women with ovarian cancer who have received three or more previous chemotherapy regimens.
Read MorePosted by | Nov 26, 2019 | Cancer |
‘+RNAinsight will help identify thousands more patients at increased risk for cancer.
Read MorePosted by | Nov 22, 2019 | Culture Media |
New kit achieves over 90% correlation rate with biopsied embryos and testing spent culture media.
Read More